Neurotensin induces tyrosine hydroxylase gene activation through nitric oxide and protein kinase C signaling pathways.

The regulation of tyrosine hydroxylase (TH) represents an effective means to control the level of catecholamines, because TH is the major limiting enzyme of monoamine biosynthesis. The neuropeptide neurotensin (NT) is a neuromodulator of dopaminergic systems, and a direct interaction between NT and TH expression has been demonstrated in vivo and in vitro. In the present work, the molecular mechanisms and signaling pathways responsible for TH gene activation have been explored. In N1E-115 cells, NT agonist induced a TH protein level increase, correlating with a significant increase in TH mRNA abundance. This cellular response was the result of TH promoter activation, via c-fos and Jun D binding at the AP-1 responsive element. Using selective protein kinase C and nitric oxide synthase inhibitors, we demonstrate, by quantitative reverse transcription-polymerase chain reaction, gel shift, and protein assays, that TH gene activation by NT agonist requires both protein kinase C stimulation and nitric oxide production. The two pathways exert distinct roles; whereas nitric oxide synthase inhibitors blocked c-fos expression, protein kinase C inhibitors blocked that of Jun D. The requirement for two distinct and concomitant pathways by NT demonstrates a very fine level of control of specificity on TH gene activation.

[1]  W. Rostène,et al.  Neurotensin: an endogenous psychostimulant? , 2002, Current opinion in pharmacology.

[2]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[3]  Jesse D. Martinez,et al.  Bile Acid-induced Activation of Activator Protein-1 Requires Both Extracellular Signal-regulated Kinase and Protein Kinase C Signaling* , 2000, The Journal of Biological Chemistry.

[4]  W. Willis,et al.  Fos expression is induced by increased nitric oxide release in rat spinal cord dorsal horn , 2000, Neuroscience.

[5]  J. Bressler,et al.  Increased AP‐1 DNA Binding Activity in PC12 Cells Treated with Lead , 1999, Journal of neurochemistry.

[6]  G. Boss,et al.  Nitric Oxide Regulation of Gene Transcription via Soluble Guanylate Cyclase and Type I cGMP-dependent Protein Kinase* , 1999, The Journal of Biological Chemistry.

[7]  M. Besson,et al.  Glutamate Induces Phosphorylation of Elk-1 and CREB, Along with c-fos Activation, via an Extracellular Signal-Regulated Kinase-Dependent Pathway in Brain Slices , 1999, Molecular and Cellular Biology.

[8]  R. Spanagel,et al.  Repeated Administration of the Neurotensin Receptor Antagonist SR 48692 Differentially Regulates Mesocortical and Mesolimbic Dopaminergic Systems , 1998, Journal of neurochemistry.

[9]  P. Forgez,et al.  Activation of Receptor Gene Transcription Is Required to Maintain Cell Sensitization after Agonist Exposure , 1998, The Journal of Biological Chemistry.

[10]  C. Alling,et al.  Stimulation of Muscarinic Receptors Induces Expression of Individual fos and jun Genes Through Different Transduction Pathways , 1998, Journal of neurochemistry.

[11]  J. Haycock Short‐ and Long‐Term Regulation of Tyrosine Hydroxylase in Chromaffin Cells by VIP and PACAP a , 1996, Annals of the New York Academy of Sciences.

[12]  C. Kilts,et al.  Neurotensin induces Fos and Zif268 expression in limbic nuclei of the rat brain , 1996, Neuroscience.

[13]  P. Forgez,et al.  Quantitative RT-PCR: limits and accuracy. , 1996, BioTechniques.

[14]  K. Vrana,et al.  Intricate Regulation of Tyrosine Hydroxylase Activity and Gene Expression , 1996, Journal of neurochemistry.

[15]  B. Spiegelman,et al.  Differentiation of mouse keratinocytes is accompanied by PKC-dependent changes in AP-1 proteins. , 1996, Oncogene.

[16]  J. Mallet The TiPS/TINS lecture. Catecholamines: from gene regulation to neuropsychiatric disorders. , 1996, Trends in pharmacological sciences.

[17]  T. Joh,et al.  AP1‐Mediated Transcriptional Enhancement of the Rat Tyrosine Hydroxylase Gene by Muscarinic Stimulation , 1996, Journal of neurochemistry.

[18]  L. Ignarro,et al.  The cloned neurotensin receptor mediates cyclic GMP formation when coexpressed with nitric oxide synthase cDNA. , 1994, Molecular pharmacology.

[19]  D. Gully,et al.  Increase in neurotensin receptor expression in rat brain induced by chronic treatment with the nonpeptide neurotensin receptor antagonist SR 48692 , 1994, Neuroscience Letters.

[20]  K. Pennypacker,et al.  Pharmacological regulation of AP‐1 transcription factor DNA binding activity 1 , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  D. Gully,et al.  SR 48692 inhibits neurotensin-induced [3H]dopamine release in rat striatal slices and mesencephalic cultures. , 1994, European journal of pharmacology.

[22]  M. Therrien,et al.  Cell-specific helix-loop-helix factor required for pituitary expression of the pro-opiomelanocortin gene , 1993, Molecular and cellular biology.

[23]  S. Berry,et al.  Evidence for protein kinase-C mediation of the neurotensin-induced activation of tyrosine hydroxylase in tuberoinfundibular dopaminergic neurons. , 1992, Endocrinology.

[24]  E. Richelson,et al.  Developmental regulation of neurotensin receptor expression and function in murine neuroblastoma clone N1E-115. , 1991, European journal of pharmacology.

[25]  J. Mallet,et al.  Transcriptional and post‐transcriptional regulation of tyrosine hydroxylase gene by protein kinase C. , 1990, The EMBO journal.

[26]  Masayuki Masu,et al.  Structure and functional expression of the cloned rat neurotensin receptor , 1990, Neuron.

[27]  M. Stachowiak,et al.  Short and long term regulation of catecholamine biosynthetic enzymes by angiotensin in cultured adrenal medullary cells. Molecular mechanisms and nature of second messenger systems. , 1990, The Journal of biological chemistry.

[28]  P. Kitabgi,et al.  Neurotensin, bradykinin and somatostatin inhibit cAMP production in neuroblastoma N1E115 cells via both pertussis toxin sensitive and insensitive mechanisms. , 1989, Biochemical and biophysical research communications.

[29]  M. Yaniv,et al.  Characterization of junD: a new member of the jun proto‐oncogene family. , 1989, The EMBO journal.

[30]  I. Verma,et al.  fos-associated cellular p39 is related to nuclear transcription factor AP-1 , 1988, Cell.

[31]  E. Richelson,et al.  Desensitization of neurotensin receptor-mediated cyclic GMP formation in neuroblastoma clone N1E-115. , 1988, Biochemical pharmacology.

[32]  P. Kitabgi,et al.  Stimulation of Inositol Phosphate Production by Neurotensin in Neuroblastoma N1E115 Cells: Implication of GTP‐Binding Proteins and Relationship with the Cyclic GMP Response , 1987, Journal of neurochemistry.

[33]  T. Hökfelt,et al.  Occurrence of neurotensinlike immunoreactivity in subpopulations of hypothalamic, mesencephalic, and medullary catecholamine neurons , 1984, The Journal of comparative neurology.

[34]  M. Bräutigam,et al.  Mouse neuroblastoma clone N1E-115: a suitable model for studying the action of dopamine agonists of tyrosine hydroxylase activity. , 1982, Biochemical pharmacology.

[35]  E. Richelson,et al.  REGULATION OF TYROSINE HYDROXYLASE ACTIVITY IN MOUSE NEUROBLASTOMA CLONE N1E‐115 , 1973, Journal of neurochemistry.

[36]  S. Udenfriend,et al.  TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS. , 1964, The Journal of biological chemistry.

[37]  P. Kitabgi,et al.  Reduced peptide bond pseudopeptide analogues of neurotensin. , 1992, Peptide research.

[38]  A. Beaudet,et al.  Correspondence between high affinity 125I‐neurotensin binding sites and dopaminergic neurons in the rat substantia nigra and ventral tegmental area: A combined radioautographic and immunohistochemical light microscopic study , 1989, The Journal of comparative neurology.